DP brings groundbreaking ENT cell therapy to the UK and Ireland

Renowned ENT supplier, DP Medical Systems, has secured the exclusive distribution rights to bring Tropocells® PRP to the UK and Ireland for use in ENT procedures, more recently for the management of voice conditions such as scarring of the voice box, sulcus vocalis (an indentation or furrowing of the vocal fold), and vocal fold atrophy commonly due to age-related changes.

Tropocells® uses platelet-rich plasma (PRP) therapy, which is prepared from a patient’s own blood and contains a concentration of platelets and growth factors. The PRP is then injected into the targeted site on the vocal folds with the aim of supporting tissue repair and regeneration.

The process promotes natural healing and, by utilising patients’ own biological resources, minimises the risk of side effects or tissue reactions, as the treatment does not involve synthetic or foreign materials.

Trials of the innovation are already underway at Guy’s Hospital in London, with consultant ENT surgeon and laryngologist Shiying Hey and her team being  among the first in the UK to explore the treatment for laryngeal conditions within an NHS setting.

So far, Shiying and her team has already treated more than ten patients using the product, supplied by DP Medical.

Shiying Hey said: “Voice disorders such as vocal fold scarring, sulcus and atrophy can often be difficult to treat. Our current approaches include voice therapy, injection treatments such as fillers or steroids depending on the condition, and in some cases surgery. These can be helpful, but outcomes can also be variable.

“Regenerative treatments such as PRP are therefore very exciting, as they are generally safe and have the potential to support tissue healing and remodelling, thereby improving the quality of the vocal fold tissue itself. While we are still at an early stage, having a new option for patients with these challenging voice conditions and seeing encouraging early results so far is very promising.”

Alongside Tropocells® PRP, DP Medical Systems is also exclusively supplying Tropocells® PRF – a platelet rich fibrin product which promotes cell growth within the jaw by using a patient’s own blood to form a clot, and TropoVISC™ - a 100% natural injectable material that keeps Tropocells® PRP at the injection site.

Owen Pemberton, managing director at DP Medical, said: “The Tropocells® product range has such incredible potential to revolutionise the way many ENT conditions, such as voice problems, are treated.

“We’re really excited to be the only company distributing this pioneering product for use in ENT applications in the UK and Ireland, and we’re thrilled to see the first cases going so well with Shiying and her team at Guy’s Hospital.”

For further information about Tropocells® and DP Medical’s wider product range, visit www.dpmedicalsys.com